Augmented renal clearance

Last updated

In pharmacology, augmented renal clearance (ARC) is a phenomenon where certain critically ill patients may display increased clearance of a medication through the kidneys. In many cases, it is observed as a measured creatinine clearance above that which is expected given the patient's age, gender, and other factors. The phenomenon is most commonly observed in patients with neurologic damage, sepsis, major trauma, or burns.

Contents

Augmented renal clearance can be caused by increased fluid administration, certain medications, and critical illnesses. It can lead to failure of treatment in people due to a decrease in drug concentrations, increase in clearance, or shorter half life. Many medications require adjustment to account for the changed clearance in people with ARC, notably some antibiotics.

History

Normal kidney function measured by creatinine clearance varies in different populations based on age, gender, race, fluid balance, and other factors, but also can be affected by diseases themselves. [1] This makes it challenging to assign an objective number or scale to kidney function. For this reason, kidney function (and thus medication elimination) has been approximated by measuring creatinine clearance, or calculating an estimated glomerular filtration rate (eGFR), since 1976. [2] Beginning in the late 1970s, an increase in the creatinine clearance had been observed in burn patients. [3] [4] This led to the realization that some burn patients required higher than expected doses of aminoglycosides to obtain the same serum concentration of drug. [4]

Diagnosis

The primary sign of augmented renal clearance is an increase in the creatinine clearance well above that which would be considered normal. Commonly, ARC is defined as a creatinine clearance of greater than 130 mL/min, but the effects of increased clearance on therapy are not directly correlated to a specific number. For this reason, lower cutoffs such as 120 mL/min are used by some, as well as higher cutoffs in young people who typically have higher kidney function to begin with. Another cutoff used is 10% above the upper limit of normal for a certain population. [1]

In patients who do not have their creatinine clearance or eGFR measured or calculated frequently, augmented renal clearance may be first seen by the failure of certain medications to produce the expected effect in a patient. As an example, an antibiotic that is being administered at recommended doses in accordance with antibiotic sensitivity testing may not be inducing clinical improvement in a person. This may also be recognized if calculated dosages based on pharmacokinetic monitoring are higher than expected for a patient. [4]

Causes

Shannon et al. observed in 1932 that dogs had an increased renal function after high protein meals – which they termed "renal function reserve". [5] Activation of this "reserve" or extra-renal function has been suggested as a potential mechanism for ARC in severe illness. [3]

The administration of medications which increase blood flow to the kidneys has also been considered a potential cause of ARC, including administration of fluids. [6] Some medications which have been thought to cause increased renal clearance include norepinephrine and other vasopressors. While medications may increase renal clearance, many patients with severe illness have higher clearance prior to the initiation of these medications. [1] Augmented renal clearance also may occur in people who have some types of cancers, such as hematologic cancers. In these people, the efficacy of antibiotic treatment may be decreased if the increased clearance is not accounted for. [6]

Risk factors and screening

Patients with critical illnesses can be screened for risk of ARC affecting therapy in a number of ways. Scoring methods may use factors such as the following to predict ARC in critically ill patients:

Management

Augmented renal clearance may result in failure of treatment due to the increased elimination of drugs. This can be prevented by increasing the dosage of the medication, or by increasing the frequency the medication is administered to account for increased elimination. ARC influences the recommended dosages for antibiotics including aminoglycosides, beta-lactams, fluoroquinolones, and vancomycin in critical care. In any case, the occurrence of ARC is managed through pharmacokinetic monitoring and adjusting medication dosages, frequencies, or timing to ensure adequate response. [1]

The occurrence of ARC can also impact medications that are unrelated to an acute illness, such as levetiracetam for seizures. People taking a stable dose of levetiracetam at home may require an increased dose when critically ill in a hospital to maintain efficacy. [9]

Epidemiology

Occurrence of ARC by disease [4]
Disease stateARC (CrCl >130 mL/min)
Severe burn65%
Sepsis39.5–56%
Subarachnoid hemorrhage100%
Trauma85.7%
Traumatic brain injury85%

Augmented renal clearance can occur in many critical care instances, but is common when patients are administered large quantities of fluid replacement, as is common in an intensive care unit. It is considered a normal part of the body's response to a severe infection or other traumatic event. Changes in renal function due to trauma or infection may be in part due to changes in hormone release as part of the body's immune and healing responses. [4]

Related Research Articles

<span class="mw-page-title-main">Creatinine</span> Breakdown product of creatine phosphate

Creatinine is a breakdown product of creatine phosphate from muscle and protein metabolism. It is released at a constant rate by the body.

<span class="mw-page-title-main">Vancomycin</span> Pharmaceutical drug

Vancomycin is a glycopeptide antibiotic medication used to treat a number of bacterial infections. It is used intravenously as a treatment for complicated skin infections, bloodstream infections, endocarditis, bone and joint infections, and meningitis caused by methicillin-resistant Staphylococcus aureus. Blood levels may be measured to determine the correct dose. Vancomycin is also taken orally as a treatment for severe Clostridium difficile colitis. When taken orally it is poorly absorbed.

<span class="mw-page-title-main">Kidney failure</span> Disease where the kidneys fail to adequately filter waste products from the blood

Kidney failure, also known as end-stage kidney disease, is a medical condition in which the kidneys can no longer adequately filter waste products from the blood, functioning at less than 15% of normal levels. Kidney failure is classified as either acute kidney failure, which develops rapidly and may resolve; and chronic kidney failure, which develops slowly and can often be irreversible. Symptoms may include leg swelling, feeling tired, vomiting, loss of appetite, and confusion. Complications of acute and chronic failure include uremia, hyperkalaemia, and volume overload. Complications of chronic failure also include heart disease, high blood pressure, and anaemia.

<span class="mw-page-title-main">Uremia</span> Type of kidney disease, urea in the blood

Uremia is the term for high levels of urea in the blood. Urea is one of the primary components of urine. It can be defined as an excess in the blood of amino acid and protein metabolism end products, such as urea and creatinine, which would be normally excreted in the urine. Uremic syndrome can be defined as the terminal clinical manifestation of kidney failure. It is the signs, symptoms and results from laboratory tests which result from inadequate excretory, regulatory, and endocrine function of the kidneys. Both uremia and uremic syndrome have been used interchangeably to denote a very high plasma urea concentration that is the result of renal failure. The former denotation will be used for the rest of the article.

<span class="mw-page-title-main">Furosemide</span> Loop diuretic medication

Furosemide is a loop diuretic medication used to treat edema due to heart failure, liver scarring, or kidney disease. It had many trade names including Discoid, Frusemide, Lasix and Uremide. Furosemide may also be used for the treatment of high blood pressure. It can be taken intravenously or orally. When given intravenously, furosemide typically takes effect within five minutes; when taken orally, it typically metabolizes within an hour.

<span class="mw-page-title-main">Glomerular filtration rate</span> Renal function test

Renal functions include maintaining an acid–base balance; regulating fluid balance; regulating sodium, potassium, and other electrolytes; clearing toxins; absorption of glucose, amino acids, and other small molecules; regulation of blood pressure; production of various hormones, such as erythropoietin; and activation of vitamin D.

<span class="mw-page-title-main">Acute kidney injury</span> Medical condition

Acute kidney injury (AKI), previously called acute renal failure (ARF), is a sudden decrease in kidney function that develops within 7 days, as shown by an increase in serum creatinine or a decrease in urine output, or both.

<span class="mw-page-title-main">Chronic kidney disease</span> Medical condition

Chronic kidney disease (CKD) is a type of kidney disease in which a gradual loss of kidney function occurs over a period of months to years. Initially generally no symptoms are seen, but later symptoms may include leg swelling, feeling tired, vomiting, loss of appetite, and confusion. Complications can relate to hormonal dysfunction of the kidneys and include high blood pressure, bone disease, and anemia. Additionally CKD patients have markedly increased cardiovascular complications with increased risks of death and hospitalization.

<span class="mw-page-title-main">Loop diuretic</span> Diuretics that act at the ascending limb of the loop of Henle in the kidney

Loop diuretics are diuretics that act on the Na-K-Cl cotransporter along the thick ascending limb of the loop of Henle in nephrons of the kidneys. They are primarily used in medicine to treat hypertension and edema often due to congestive heart failure or chronic kidney disease. While thiazide diuretics are more effective in patients with normal kidney function, loop diuretics are more effective in patients with impaired kidney function.

Nephrotoxicity is toxicity in the kidneys. It is a poisonous effect of some substances, both toxic chemicals and medications, on kidney function. There are various forms, and some drugs may affect kidney function in more than one way. Nephrotoxins are substances displaying nephrotoxicity.

<span class="mw-page-title-main">Hepatorenal syndrome</span> Human disease

Hepatorenal syndrome is a life-threatening medical condition that consists of rapid deterioration in kidney function in individuals with cirrhosis or fulminant liver failure. HRS is usually fatal unless a liver transplant is performed, although various treatments, such as dialysis, can prevent advancement of the condition.

<span class="mw-page-title-main">Docetaxel</span> Chemotherapy medication

Docetaxel, sold under the brand name Taxotere among others, is a chemotherapy medication used to treat a number of types of cancer. This includes breast cancer, head and neck cancer, stomach cancer, prostate cancer and non-small-cell lung cancer. It may be used by itself or along with other chemotherapy medication. It is given by slow injection into a vein.

<span class="mw-page-title-main">Piperacillin</span> Chemical compound

Piperacillin is a broad-spectrum β-lactam antibiotic of the ureidopenicillin class. The chemical structure of piperacillin and other ureidopenicillins incorporates a polar side chain that enhances penetration into Gram-negative bacteria and reduces susceptibility to cleavage by Gram-negative beta lactamase enzymes. These properties confer activity against the important hospital pathogen Pseudomonas aeruginosa. Thus piperacillin is sometimes referred to as an "anti-pseudomonal penicillin".

In pharmacology, clearance is a pharmacokinetic measurement of the volume of plasma from which a substance is completely removed per unit time. Usually, clearance is measured in L/h or mL/min. The quantity reflects the rate of drug elimination divided by plasma concentration. Excretion, on the other hand, is a measurement of the amount of a substance removed from the body per unit time. While clearance and excretion of a substance are related, they are not the same thing. The concept of clearance was described by Thomas Addis, a graduate of the University of Edinburgh Medical School.

Contrast-induced nephropathy (CIN) is a purported form of kidney damage in which there has been recent exposure to medical imaging contrast material without another clear cause for the acute kidney injury.

<span class="mw-page-title-main">Acecainide</span> Antiarrythmic drug

Acecainide is an antiarrhythmic drug. Chemically, it is the N-acetylated metabolite of procainamide. It is a Class III antiarrhythmic agent, whereas procainamide is a Class Ia antiarrhythmic drug. It is only partially as active as procainamide; when checking levels, both must be included in the final calculation.

<span class="mw-page-title-main">Cystatin C</span>

Cystatin C or cystatin 3, a protein encoded by the CST3 gene, is mainly used as a biomarker of kidney function. Recently, it has been studied for its role in predicting new-onset or deteriorating cardiovascular disease. It also seems to play a role in brain disorders involving amyloid, such as Alzheimer's disease. In humans, all cells with a nucleus produce cystatin C as a chain of 120 amino acids. It is found in virtually all tissues and body fluids. It is a potent inhibitor of lysosomal proteinases and probably one of the most important extracellular inhibitors of cysteine proteases. Cystatin C belongs to the type 2 cystatin gene family.

<span class="mw-page-title-main">Cephaloridine</span> Chemical compound

Cephaloridine is a first-generation semisynthetic derivative of antibiotic cephalosporin C. It is a Beta lactam antibiotic, like penicillin. Its chemical structure contains 3 cephems, 4 carboxyl groups and three pyridinium methyl groups.

<span class="mw-page-title-main">Voclosporin</span> Chemical compound

Voclosporin, sold under the brand name Lupkynis, is a calcineurin inhibitor used as an immunosuppressant medication for the treatment of lupus nephritis. It is an analog of ciclosporin that has enhanced action against calcineurin and greater metabolic stability.

Renal angina is a clinical methodology to risk stratify patients for the development of persistent and severe acute kidney injury (AKI). The composite of risk factors and early signs of injury for AKI, renal angina is used as a clinical adjunct to help optimize the use of novel AKI biomarker testing. The term angina from Latin and from the Greek ankhone ("strangling") are utilized in the context of AKI to denote the development of injury and the choking off of kidney function. Unlike angina pectoris, commonly caused due to ischemia of the heart muscle secondary to coronary artery occlusion or vasospasm, renal angina carries no obvious physical symptomatology. Renal angina was derived as a conceptual framework to identify evolving AKI. Like acute coronary syndrome which precedes or is a sign of a heart attack, renal angina is used as a herald sign for a kidney attack. Detection of renal angina is performed by calculating the renal angina index.

References

  1. 1 2 3 4 Udy, Andrew A.; Roberts, Jason A.; Boots, Robert J.; Paterson, David L.; Lipman, Jeffrey (January 2010). "Augmented Renal Clearance: Implications for Antibacterial Dosing in the Critically Ill". Clinical Pharmacokinetics. 49 (1): 1–16. doi: 10.2165/11318140-000000000-00000 . PMID   20000886. S2CID   41595499.
  2. Cockcroft, Donald W.; Gault, Henry (1976). "Prediction of Creatinine Clearance from Serum Creatinine". Nephron. 16 (1): 31–41. doi:10.1159/000180580. PMID   1244564.
  3. 1 2 Cook, Aaron M.; Hatton‐Kolpek, Jimmi (March 2019). "Augmented Renal Clearance". Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy. 39 (3): 346–354. doi:10.1002/phar.2231. PMID   30723936. S2CID   73441602.
  4. 1 2 3 4 5 Atkinson, Arthur J. (2018). "Augmented renal clearance". Translational and Clinical Pharmacology. 26 (3): 111–114. doi: 10.12793/tcp.2018.26.3.111 . PMC   6989233 . PMID   32055559.
  5. Shannon, James A.; Jolliffe, Norman; Smith, Homer W. (31 August 1932). "THE EXCRETION OF URINE IN THE DOG: IV. The Effect of Maintenance Diet, Feeding, etc., Upon the Quantity of Glomerular Filtrate". American Journal of Physiology. Legacy Content. 101 (4): 625–638. doi:10.1152/ajplegacy.1932.101.4.625.
  6. 1 2 Izumisawa, Tomohiro; Kaneko, Tomoyoshi; Soma, Masakazu; Imai, Masahiko; Wakui, Nobuyuki; Hasegawa, Hideo; Horino, Tetsuya; Takahashi, Noriko (1 December 2019). "Augmented Renal Clearance of Vancomycin in Hematologic Malignancy Patients". Biological and Pharmaceutical Bulletin. 42 (12): 2089–2094. doi: 10.1248/bpb.b19-00652 . PMID   31534058.
  7. 1 2 3 Saito, Kazuki; Kamio, Satomi; Ito, Kanako; Suzuki, Norifumi; Abe, Kensuke; Goto, Tatsuya (4 June 2020). "A simple scoring method to predict augmented renal clearance in haematologic malignancies". Journal of Clinical Pharmacy and Therapeutics. 45 (5): 1120–1126. doi: 10.1111/jcpt.13193 . PMID   32497262. S2CID   219327146.
  8. 1 2 3 Nei, Andrea M.; Kashani, Kianoush B.; Dierkhising, Ross; Barreto, Erin F. (2020). "Predictors of Augmented Renal Clearance in a Heterogeneous ICU Population as Defined by Creatinine and Cystatin C". Nephron. 144 (7): 313–320. doi: 10.1159/000507255 . PMC   7371523 . PMID   32428906.
  9. Spencer, Dustin D; Jacobi, Judith; Juenke, Joetta M; Fleck, James D; Kays, Michael B (October 2011). "Steady-State Pharmacokinetics of Intravenous Levetiracetam in Neurocritical Care Patients". Pharmacotherapy. 31 (10): 934–941. doi:10.1592/phco.31.10.934. PMID   21950640. S2CID   12186689.